ABSTRACT
Purpose: To study the corelation between outer retinal layer thickness (ORL), outer photoreceptor segment thickness (PROS), and central macular thickness (CMT) with best?corrected visual acuity (BCVA) in patients having clinically significant macular edema (CSME) and compare these parameters with normal patients. Methods: This was a prospective, nonrandomized, observational, comparative study done during the period of January to May 2019. The study included 60 eyes of 36 patients. The patient population was segregated into two Groups: Group ? (30 normal eyes of 15 normal patients) and Group ?? (30 eyes of 21 diabetic patients) with CSME. The comparison between ORL, PROS, and CMT was made between both the groups, and the correlation between ORL thickness, PROS thickness, and CMT with BCVA in Group ?? was studied. Results: The mean age in Group I was 52.6+10.66 years, and 53.42+8.15 years in Group II. The male/ female ratio was 1.1:1 in Group I and 4:3 in Group II. The mean CMT was greater in Group ?? (330.13 ± 37.01) than in Group ? (222.20 ± 12.30). The mean ORL thickness was greater in Group ? (97.73 ± 6.92) than in Group ?? (80.63 ± 9.03). The PROS thickness was statistically significant in Group ? (35.05 ± 3.4) than in Group ?? (28.57 ± 3.53). There was a strong correlation between BCVA and ORL thickness (r = ?0.580, P < 0.001) and more strong correlation between BCVA and PROS thickness in Group ?? (r = ?0.611, P < 0.000). There was a moderate correlation between BCVA and CMT (r = 0.410, P < 0.025), and all results were statistically significant. Conclusion: Both ORL and PROS thickness were greater in healthy normal eyes than in eyes with CSME. BCVA was strongly correlated with PROS and ORL thickness and moderately associated with CMT.
ABSTRACT
AIM: To compare the efficacy of aflibercept and ranibizumab in the treatment of diabetic macular edema(DME).METHODS: Prospective randomized controlled trial. A total of 35 patients(60 eyes)with non-proliferative diabetic retinopathy complicated with DME confirmed in our hospital from June 2020 to September 2021 were included. Intravitreal injection was performed using the 3+PRN protocol in all cases, of which 17 cases(30 eyes)received aflibercept treatment(aflibercept group)and 18 cases(30 eyes)received ranibizumab(ranibizumab group). The two groups were followed up for 12mo, observing the central macular thickness(CMT)and the best corrected visual acuity(BCVA)of the two groups, and recording the number of intravitreal injections and the occurrence of complications.RESULTS: After treatment, CMT and BCVA in the aflibercept group were significantly better than that in the ranibizumab group at 1, 3, 6 and 12 mo(all P<0.001). During the follow-up period, the number of intravitreal injections in the aflibercept group was lower than that in the ranibizumab group(4.23±0.86 vs. 6.40±0.97, P<0.05), there were no serious complications such as drug-related adverse reactions, intraocular infection, and vascular embolism in either group.CONCLUSION: Both aflibercept and ranibizumab have clear efficacy and safety in the treatment of DME, and aflibercept may be a more effective and convenient treatment option than ranibizumab for DME patients.
ABSTRACT
AIM: To observe the clinical efficacy of Yishen Yanggan Mingmu formula combined with anti-vascular endothelial growth factor(VEGF)in the treatment of wet age-related macular degeneration(wARMD).METHODS: A total of 58 patients(58 eyes)with wARMD who were treated in Ningbo Eye Hospital from September 2020 to November 2022 were collected. They were divided into two groups according to randomized digital table: 29 patients(29 eyes)for the combination group and the other 29 patients(29 eyes)for the injection group. The injection group was only given intravitreal injection of conbercept; the combination group was orally administrated with Yishen Yanggan Mingmu formula combined with intravitreal injection of conbercept. The best corrected visual acuity(BCVA), central macular thickness(CMT)and the improvement of traditional Chinese medicine(TCM)syndromes after 3mo of treatment were observed and the clinical efficacy was evaluated.RESULTS: After 3mo of treatment, the total improved effective rate of the combination group(76%)was higher than the rate of the injection group(66%). After the treatment, the BCVA of the two groups was both higher than that before treatment(P<0.05), the CMT in both groups was lower than that before the treatment(P<0.05), and the improvement of CMT of the combination group was better than the injection group(-155.93±143.79μm vs. -95.36±56.81μm, P<0.05). After 3mo of treatment, each kinds of TCM syndrome in the combination group were significantly improved compared with those syndromes before the treatment(P<0.001). In the injection group, only blurred vision was improved(P<0.05). After the treatment, the scores of dizziness and insomnia, soreness and weakness of waist and knees, paleness and cold limbs, dry eyes and fatigue in the combination group were significantly lower than the injection group(P<0.001).CONCLUSIONS: The Yishen Yanggan Mingmu formula combined with intravitreal anti-VEGF drug injection is effective in the treatment of wARMD.
ABSTRACT
Objective:To investigate the expression levels of serum miR-126 and miR-9 in patients with wet age-related macular degeneration (wAMD) and their relationship with vascular endothelial growth factor (VEGF) and central macular thickness (CMT).Methods:A total of 73 wAMD patients(observation group) admitted to the ophthalmology department of Taizhou Municipal Hospital from May 2020 to May 2021 and 60 healthy subjects (control group) who underwent physical examination during the same period were selected. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression levels of miR-126 and miR-9 in serum of the two groups. Serum angiogenesis regulatory factors [VEGF, tissue inhibitor of melalloproteinuses-1 (TIMP-1), endostatin (ES), platelet-derived growth factor (PDGF)] were detected by enzyme-linked immunosorbent assay (ELISA), and CMT and intraocular pressure (IOP) were measured. Pearson correlation analysis was performed to determine the correlation between miR-126 and miR-9 and serum angiogenesis regulatory factor levels, CMT and IOP. The diagnostic value of miR-126 and miR-9 in wAMD was analyzed by receiver operating characteristic (ROC) curve.Results:The relative expression level of serum miR-126 in observation group was significantly lower than that in control group ( P<0.05) , while the relative expression level of serum miR-9 was significantly higher than that in control group ( P<0.05). The levels of serum VEGF and PDGF in observation group were significantly higher than those in control group (all P<0.05), while the levels of serum TIMP-1 and ES were significantly lower than those in control group (all P<0.05). CMT and IOP in observation group were significantly higher than those in control group (all P<0.05). The expression level of serum miR-126 in observation group was negatively correlated with serum VEGF, PDGF, CMT and IOP ( r=-0.275, -0.523, -0.302, -0.542, all P<0.05), and was positively correlated with TIMP-1 and ES ( r=0.460, 0.263, all P<0.05). Serum miR-9 expression level was positively correlated with serum VEGF, PDGF, CMT and IOP ( r=0.434, 0.438, 0.396, 0.307, all P<0.05), and was negatively correlated with TIMP-1 and ES ( r=-0.256, -0.310, all P<0.05). The area under curve (AUC) values of serum miR-126 and miR-9 in diagnosing wAMD were 0.713 and 0.847 respectively. Conclusions:The expression level of serum miR-126 is significantly decreased while the expression level of miR-9 is significantly increased in patients with wAMD. miR-126 is negatively correlated with VEGF and CMT, and miR-9 is positively correlated with VEGF and CMT, which may aggravate the disease by promoting the inflammatory response. The detection of expression levels of serum miR-126 and miR-9 is helpful to provide the reference basis for early diagnosis of wAMD and early prevention and treatment.
ABSTRACT
Purpose: To evaluate the central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) changes on spectral domain optical coherence tomography (SD?OCT) after cataract surgery with intraocular lens (IOL) implantation in a pediatric population. Methods: This was a longitudinal, prospective, interventional study which included 90 pediatric patients who underwent cataract extraction with IOL implantation. Serial SD?OCT scans were done at postoperative day 1, 1?month, and 3?month follow?up. CMT and SFCT were measured at each visit. Results: A statistically significant increase in CMT was noted at 1 month (from 199.3 ?m to 210.04 ?m) post surgery, which declined over a 3?month period (202.70 ?m, P = 0.0001). In case of SFCT, a constant increase was observed for over 3 months of follow?up (baseline: 296.52 ?m; 1 month: 309.04 ?m; and 3 months: 319.03 ?m, P = 0.0001). The traumatic cataract group showed more pronounced changes in CMT and SFCT than the non?traumatic cataract group. No significant difference was observed regarding these parameters between those who underwent primary posterior capsulotomy (PPC) versus those who did not. None of the patients in the study group developed cystoid macular edema. These posterior segment–related anatomical changes did not affect the final visual outcomes. Conclusion: Cataract surgery induces potential inflammatory changes in the macula and choroid in pediatric patients. Such changes are more pronounced in trauma?related cases; however, they are not significant enough to affect the visual outcomes. Similarly, the additional surgical step of PPC does not induce significant anatomical or functional changes
ABSTRACT
@#AIM: To investigate the therapeutic effect of femtosecond laser-assisted cataract surgery(FLACS)in eyes with shallow anterior chamber depth.<p>METHODS: Totally 60 eyes of 55 cataract patients with shallow anterior chamber who received cataract phacoemulsification in Tangshan eye hospital from November 2020 to February 2021 were selected, and divided into two groups according to the surgical methods on patient's subjective willingness: Patients who received FLACS were assigned to the FLACS group(28 patients, 30 eyes), and patients who received conventional Phaco(27 patients, 30 eyes)were assigned to the Phaco group. Preoperative general conditions, cumulative dissipated energy(CDE), effective phacoemulsification time(EPT), postoperative best corrected visual acuity(BCVA), uncorrected visual acuity(UCVA), endothelial cell loss rate(ECL), central macular thickness(CMT)and complications were compared and analyzed.<p>RESULTS:There was no significant difference in preoperative general data between the two groups(<i>P</i>>0.05). In both groups, UCVA at 1d, 1wk and 1mo after surgery and BCVA at 1wk and 1mo after surgery were better than those before surgery, and at 1d after surgery, UCVA in FLACS group was better than that in Phaco group, the difference was statistically significant(<i>P</i><0.05). In the FLACS group, CDE, EPT, ECL at 1wk and 1mo after surgery, and the incidence of corneal edema at 1d and 1wk after surgery were all lower than those in the Phaco group(all <i>P</i><0.05). There was no significant change in CMT in either the intragroup comparison or the intergroup comparison(<i>P</i>>0.05).<p>CONCLUSION:FLACS is safe and effective in patients with shallow anterior chamber cataract, which can significantly reduce the rate of endothelial cell loss, quickly restore vision, reduce the incidence of complications, and has no significant effect on macula.
ABSTRACT
@#AIM: To observe and analyze the efficacy of Conbercept combined with 577nm yellow subliminal micropulse laser photocoagulation in the treatment of macular edema(ME)secondary to ischemic branch retinal vein occlusion(BRVO).<p>METHODS: Totally 71 patients(71 eyes)diagnosed as ME secondary to ischemic BRVO during the period from March 2016 to March 2019 were retrospectively included, and they were divided into laser group(<i>n</i>=33, 33 eyes)and combined group(<i>n</i>=38, 38 eyes)according to the different treatment methods. The patients in the laser group all received 577nm yellow subliminal micropulse laser photocoagulation, and the patients in the combined group all received Conbercept combined with 577nm yellow subliminal micropulse laser photocoagulation. The best corrected visual acuity(BCVA), central macular thickness(CMT)and total macular volume(TMV)were compared between the two groups before treatment and at 1, 2, 3, 6, 9 and 12mo after surgery, and the therapeutic efficacy was observed and the occurrence of complications were recorded.<p>RESULTS:There were statistically significant differences in the BCVA, CMT and TMV between the two groups before and after treatment(<i>P</i><0.05), and the BCVA, CMT and TMV in the two groups at 1, 2, 3, 6, 9 and 12mo after treatment were significantly lower than those before treatment(<i>P</i><0.05), and the differences between the two groups were statistically significant(<i>P</i><0.05). During follow-up, there were 30 eyes with once laser photocoagulation, 7 eyes with twice and 1 eye with 3 times in combined group, and there were 16 eyes with once laser photocoagulation, 14 eyes with twice and 3 eyes with 3 times in laser group(<i>Z</i>=2.670, <i>P</i><0.05). There were 3 eyes of corneal epithelial exfoliation on the 1d after vitreous injection in combined group, and the symptoms disappeared after symptomatic treatment. All patients did not have serious complications such as persistent intraocular pressure increase, retinal detachment and intraocular inflammation.<p>CONCLUSION: Conbercept combined with 577nm yellow subliminal micropulse laser photocoagulation has a significant efficacy in the treatment of ME secondary to ischemic BRVO, and it can effectively improve the visual acuity and promote the macular edema absorption, and it is safe and reliable.
ABSTRACT
@#AIM: To investigate the relationship between platelet parameters and macular edema(ME)in retinal vein occlusion(RVO)patients with different OCT types.<p>METHODS: Retrospective study. A total of 126 eyes in 126 patients with RVO were enrolled in the ophthalmology department of the Fifth Affiliated Hospital of Zhengzhou University from December 2016 to February 2021, among whom, 51 eyes with central retinal vein occlusion(CRVO)were included, branch retinal vein occlusion(BRVO)included 75 eyes, 31 eyes without ME(non-ME)and 95 eyes with ME. According to the morphology of OCT, ME was divided into 26 eyes of diffuse retinal thickening(DRT), 30 eyes of cystoid macular edema(CME)and 39 eyes of serous retinal detachment(SRD), the platelet parameters of patients with different groups including platelet count(PLT), mean platelet volume(MPV), plateletcrit(PCT)and platelet distribution width(PDW)were collected and statistical analysis were performed.<p>RESULTS:The MPV value and CMT value of ME group was higher than that of Non-ME group(all <i>P</i><0.001), the MPV value of SRD group was higher than that of DRT group and CME group(all <i>P</i><0.001), but there was no statistically significant difference in MPV between DRT group and CME group(<i>P</i>=0.526), CMT in SRD group was significantly higher than that in DRT group and CME group(<i>P</i><0.001), and there was no significant difference in CMT between DRT group and CME group(<i>P</i>=0.190).<p>CONCLUSION:MPV has differences in patients with RVO ME with different OCT classifications, activated platelets may be closely related to the occurrence and development of SRD.
ABSTRACT
@#AIM: To analyse the characteristic of macular microcirculation and structural features detected by optical coherence tomography angiography(OCTA)in retinal branch vein occlusion(BRVO), and analyse the risk factors of visual acuity(VA).<p>METHODS: Eligible eyes from subjects(92 with BRVO and 38 healthy people)were included. The relationship between factors and VA was analyzed by retrospective. Vessel density affected by vein occlusion of 3×3mm2 centered on the fovea(3×3mm VD)and foveal vessel density(foveal VD)in the superficial capillary plexus(SCP)and deep capillary plexus(DCP), were measured by OCTA. Central macular thickness(CMT), neuroepithelial layer thickness and height of subcortical fluid in patients with BRVO were measured.<p>RESULTS: The DCP, SCP, FD300, density of superficial fovea, density of superficial fovea and AI of the BRVO group were significantly different with control group(<i>P</i><0.01). Multivariate regression: Age(<i>P</i>=0.033, <i>OR</i>=1.152, 95%<i>CI</i>=1.011-1.312). Density of superficial fovea(<i>P</i>=0.010, <i>OR</i>=1.260, 95%<i>CI</i>=1.056-1.504)and Macular fovea thickness(<i>P</i><0.01, <i>OR</i>=1.033, 95%<i>CI</i>=1.021-1.045)were risk factors of VA. DCP and SCP were negatively related with CMT and neuroepithelial layer(<i>P</i><0.01). CMT was positively correlated with the thickness of neuroepithelial layer and the height of subcortical fluid(<i>P</i><0.01).<p>CONCLUSION: Using OCTA, we can observe the BRVO retinal blood flow and the changes of the structure of the retinal section, and the pathological features of macular retina in BRVO patients can be observed more comprehensively. Age, density of superficial fovea and macular fovea thickness were risk factors of VA.
ABSTRACT
Purpose: To evaluate the long-term safety and efficacy of the intravitreal dexamethasone implant in the treatment of diabetic macular edema (DME) as initial therapy. Methods: A hospital-based prospective, non-comparative case study of recently detected DME patients was conducted between July 2016 and December 2017, in which30 eyes of 30 patients were studied. Presenting vision, age, gender, duration of diabetes, general and ocular examination, intraocular pressure, indirect ophthalmoscopy, fundus fluorescein angiography, optical coherence tomography (OCT), and blood sugar levels were noted. Patients with increased central macular thickness (CMT) received an intravitreal dexamethasone implant as initial therapy. All were followed up at 1 week, 1 month, 3 months, 6 months, and 1 year, and the findings were recorded and analyzed using SPSS software. Results: 30 eyes of 30 patients were studied which included 22 males and 8 females. The mean age of presentation was 58.7 ± 4.45 years. The mean decrease in CMT following intravitreal dexamethasone was 269.27 ± 112.002, 253.5 ± 108.294, and 286.73 ± 143.395 ?m at the end of 3, 6, and 12 months, respectively, and the mean improvement in visual acuity (VA) was 2.27 ± 1.70 lines at 3 months, 2.27 ± 1.83 lines at 6 months, and 1.17 ± 2.00 lines at 12 months. Out of 30 cases, 4 had persistent DME and 6 had recurrence of DME at completion of 1 year of follow-up. Conclusion: Intravitreal dexamethasone as initial therapy in the treatment of DME is both safe and efficacious in the reduction of CMT and improvement of vision and can be considered as primary therapy for DME.
ABSTRACT
@#AIM: To discuss the effect of conbercept in the treatment of polypoid chorioretinopathy(PCV)and its influence on hemorheology.<p>METHODS: From January 2017 to April 2018, 62 patients with PCV were enrolled in our hospital. According to the difference of treatment, the patients were divided into two groups, 31 cases in each group. The control group was treated with rapunzumab and the observation group with conbercept. Intraocular pressure, BCVA, CMT, SFCT, hemorheology and complications were compared between the two groups. <p>RESULTS: There was no difference in intraocular pressure, BCVA, CMT and SFCT between the two groups before treatment(<i>P</i>>0.05). With the increase of time, BCVA increased, CMT and SFCT decreased in both groups(<i>P</i><0.05). BCVA, CMT and SFCT were different between the two groups(<i>P</i><0.05). There was no difference in intraocular pressure between the two groups before and after treatment(<i>P</i>>0.05). The whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity and RBC aggregation index in the observation group were lower than those before treatment and lower than those in the control group(<i>P</i><0.05), and the RBC deformation index was higher than that before treatment and higher than that in the control group(<i>P</i><0.05). There was no difference in the incidence of complications between the two groups(3% <i>vs</i> 6%, <i>P</i>>0.05).<p>CONCLUSION: The application of conbercept in PCV can improve the visual acuity, and have a good impact in the hemorheology, reduce the macular edema and other clinical symptoms, and it has high safety and no effect on intraocular pressure.
ABSTRACT
@#Cataract is the most common blinding eye disease in our country. Cataract phacoemulsification combined with intraocular lens implantation is the first choice for cataract surgery, with advantages of a small incision, mild anterior chamber reaction, repaid recovery and small astigmatism of corneal. However, there are still some patients failed to achieve ideal visual quality after surgery due to various reasons even if the surgery is successful. Cystoid macular edema(CME)is one of the common complications in pseudophakic eyes affecting postoperative visual quality after cataract surgery. Recent studies on pseudophakic cystoid macular edema(PCME)are reviewed in this paper.
ABSTRACT
Aim: This study aims to assess central macular thickness (CMT) using optical coherence tomography (OCT) in diabetic patientsbefore and after phacoemulsification.Materials and Methods: A prospective study on 90 diabetic patients conducted from February 2018 to February 2019, whowere all operated for cataract by phacoemulsification. Complete ophthalmological evaluation was done preoperatively. CMTwas measured preoperatively using spectral-domain (SD) OCT. Patients were followed at the 1st post-operative day and at 1, 4,and 6 weeks postoperatively. OCT was done during the 6th week of post-operative period.Results: The mean central 1 mm subfield macular thickness, preoperatively and 6th week postoperatively was 205.12 ± 24.85 µmand 212.79 ± 28.29 µm, respectively. The difference between pre-operative and 6th week post-operative CSMT was significantin all the three groups (no diabetic retinopathy (DR), mild non-proliferative DR [NPDR], and moderate NPDR) (P = 0.001).Conclusion: SD-OCT detected statistically significant increase in mean CMT at 6-week postoperatively in diabetic patientsundergoing phacoemulsification. Precise surgical technique, in the bag implantation of intraocular lens and good post-operativecare, blood sugar control reduces the occurrence of macular edema, resulting in good visual outcome.
ABSTRACT
@#AIM: To compare the efficacy and safety of 577nm subthreshold micropulse laser(SML)and photodynamic therapy(PDT)in patients with chronic central serous chorioretinopathy(cCSC).<p>METHODS: Thirty patients(30 eyes)with cCSC were treated in our hospital from February 2015 to April 2018. And 15 patients(15 eyes)were treated with SML(577 nm)while the others were treated by PDT. The BCVA and CMT as well as complications were observed at 1, 3, 6mo after treatment.<p>RESULTS: At 1mo after treatment, BCVA was increased to 0.37±0.13 in SML group and 0.20±0.11 in PDT group(<i>t</i>=-3.93, <i>P</i><0.001); CMT was decreased to 382.80±76.54μm in SML group and 247.60±28.46μm in PDT group(<i>t</i>=-6.41, <i>P</i><0.001). Although improvements of BCVA and CMT were both achieved in two groups, improvements in PDT group were better than those in SML group. At 3mo and 6mo after treatment, both BCVA and CMT were no significant difference between the two groups(<i>P</i>>0.05). During the follow-up period, there were no obvious complications or recurrence observed.<p>CONCLUSION: Both SML(577nm)and PDT were effective and safe in the treatment of cCSC, but the theraputic effects of PDT was slightly quicker than SML. Further, with the prolongation of recovery time, the curative effects of these treatments were similar. Additionally, SML(577nm)costs was much cheaper than PDT and had no risk of injury or allergy for patients, and patients with cCSC could also be treated repeatedly using it.
ABSTRACT
@#AIM: To study the effect of vitrectomy combined with macular epiretinal membrane peeling on visual acuity, central macular thickness(CMT)and metamorphopsia degree in patients with idiopathic macular epiretinal membrane(IMEM).<p>METHODS: Totally 31 cases(31 eyes)of patients with IMEM were treated with vitrectomy combined with macular epiretinal membrane peeling, and the best corrected visual acuity(BCVA), CMT, ellipsoid zone(IS/OS)connectivity and macular morphology were examined before and after operation. The treatment effect was assessed, and the relationship between BCVA, macular structure and morphology before and after operation was studied. All the factors that might affect the surgical outcomes were analyzed.<p>RESULTS: The mean BCVA and CMT were 0.59±0.14 and 429.35±86.17μm respectively before operation, and were decreased to 0.38±0.09 and 304.87±62.54μm at 6mo after operation(<i>P</i><0.05). The metamorphopsia degree after operation was gradually decreased, and the metamorphopsia degree at 1, 3 and 6mo after operation was lower than before operation(<i>P</i><0.008). At 1mo after operation, the IS/OS connectivity ratios were 65%, and there was no significant difference compared with that before operation with 52%(<i>P</i>>0.008). The ratio of IS/OS connectivity was 81% and 90% at 3mo and 6mo after operation, and the difference was statistically significant compared with that before operation(<i>P</i><0.008). There was significant difference in the macular morphology at different time after operation(<i>P</i><0.008). The proportions of patients with normal macular morphology at 1, 3 and 6mo after operation were 26%, 52% and 77% respectively, and the differences were statistically significant compared with before operation(<i>P</i><0.008). Pearson or Spearman correlation analysis showed postoperative BCVA in IMEM patients was positively correlated with preoperative BCVA and postoperative CMT(<i>P</i><0.05), but that was negatively correlated with preoperative macular morphology, preoperative and postoperative IS/OS connectivity and postoperative macular morphology(<i>P</i><0.05).<p>CONCLUSION: Vitrectomy combined with macular epiretinal membrane peeling can significantly reduce the CMT of patients with IMEM, and improve the IS/OS connectivity and macular morphology, so as to improve the visual acuity and reduce the metamorphopsia degree.
ABSTRACT
@#AIM: To investigate the efficacy and safety of conbercept intravitreal injection combined with selective laser photocoagulation for central retinal vein occlusion(CRVO).<p>METHODS: A retrospective study was performed on 66 patients with CRVO in our department of ophthalmology. Among them, 30 patients received only conbercept's intravitreal injection and served as a control group. On this basis, another 36 patients were combined with selective laser photocoagulation and as an observation group. The differences of central macular thickness(CMT), BCVA(LogMAR)and complication rate after treatment were compared between the two groups.<p>RESULTS:The CMT and BCVA of the two groups were significantly improved after treatment(<i>P</i><0.05). The CMT and BCVA of the observation group were significantly better than the control group at 6th month after treatment(<i>P</i><0.05). The number of intravitreal injections in the observation group was significantly lower than that in the control group(<i>P</i><0.05). There was no significant difference in the complications(<i>P</i>>0.05).<p>CONCLUSION: The combination therapy has a more significant effect on CRVO and is safe.
ABSTRACT
@#AIM: To determine the relationship among the macular pigment optical density(MPOD), central macular thickness and body mass index(BMI).<p>METHODS: This is a comparative cross-sectional study performed in a single institution. Totally 210 volunteers who met the inclusion criteria were included in this study. The subject's MPOD was measured using Macula Pigment Screener II(MPS II, by Electron Technology). Central macular thickness was measured with Spectral Domain Cirrus Optical Coherence Tomography(OCT), Cirrus(Model 4000, Carl Zeiss Meditec). The information of both MPOD and OCT from both eyes were recorded. The data was analysed using Microsoft© Excel \〖Version 15.12.3(150724)℃2015 Microsoft\〗, SPSS(IBM© SPSS© Statistics Version 2.2), and R(version 3.2.1; R Core Team 2015).<p>RESULTS: There was significant positive correlation between MPOD and central macular thickness(<i>r</i>=0.42, <i>P</i><0.01)and a significant negative correlation between MPOD and BMI(<i>r</i>=-0.23, <i>P</i><0.01).<p>CONCLUSION: Our study showed a significant positive correlation between MPOD and central macular thickness. Further study is needed to look at the detailed structure of the fovea and its relationship with MPOD. Our study also found a significant negative correlation between MPOD and BMI, suggesting that a reduction in BMI may increase the density of macula pigment, which can be helpful in preventing age-retinal pigment epitheliitis(ARMD).
ABSTRACT
@#AIM:To evaluate the changes of macular retinal vessel density after the first intravitreal anti-vascular endothelial growth factor(VEGF)injection for macular edema secondary to retinal vein occlusion. <p>METHODS: A retrospective case control series, 23 cases with RVO secondary macular edema were included from April 2018 to July 2018. They were treated with 0.5mg/0.05mL intravitreal injection of conbercept. To compare the best corrected visual acuity(BCVA)before and after treatment. Optical coherence tomography angiography(OCTA)images was obtained, central macular thickness(CMT)and vessel length density and perfusion density in the superficial retinal capillary plexus were measured before and after intravitreal injection.<p>RESULTS: The mean interval between baseline and follow up was 1mo. The improvement of BCVA, the decreased value of average central macular thickness after treatment were better than before(<i>P</i><0.05). The vessel length density and perfusion density at the central, inner and full region in the superficial retinal capillary plexus was not significantly different after intravitreal injection(<i>P</i>>0.05).<p>CONCLUSION: The average BCVA and the mean CMT of patients with RVO secondary macular edema after treatment was significantly better, and it is not progressive macular ischemia in the short-term after a single intravitreal injection of an anti-VEGF agent.
ABSTRACT
@#AIM: To compare the efficacy of the laser photocoagulation with combination therapy of both the laser potocoagulation and ranibizumab in the treatment of diabetic macular edema(DME).<p>METHODS: The research was based on the randomized controlled trial(RCT). A total of 180 eyes from 134 cases diagnosed with DME were randomly divided into experimental group and control group. No statistically significant difference was found between two groups(<i>P</i>>0.05)with respect to age, sex, duration of disease, best corrected visual acuity(BCVA), the mean intraocular pressure(IOP)and the mean central macular thickness(CMT). Patients in the control group received the photocoagulation while the combination therapy of both laser photocoagulation and ranibizumab were employed in the experimental group. BCVA, IOP and CMT were assessed at 1wk and 3mo after treatment, and the collecting data of two groups were examined.<p>RESULTS: Before treatment, 1wk and 3mo after treatment, there was no significant difference of IOP(<i>P</i>>0.05). 1wk and 3mo after treatment, the CMT in the experimental group was significantly lower than the other(<i>t</i>= -7.83, -8.80, <i>P</i><0.05), whilst the BCVA in the experimental group was significantly higher than that in the control group(<i>t</i>= -3.76, -4.09, <i>P</i><0.05). The BCVA of the experimental group was increased after 1wk treatment(<i>t</i>=1.97, <i>P</i><0.05). The recurrence rate of the experimental group was lower(χ2=4.59, <i>P</i><0.05). There were no significant differences in the incidence of early intraocular pressure between the two groups(χ2=0.03, <i>P</i>>0.05). No retinal detachment or intraocular inflammation occurred in both groups.<p>CONCLUSION: Compared with the laser photocoagulation, the combination therapy of laser photocoagulation and ranibizumab could significantly lower the CMT after surgery, early improve the BCVA and decrease the recurrence rate.
ABSTRACT
PURPOSE: To determine changes in subfoveal choroidal thickness (SCT) after intravitreal injection of bevacizumab in eyes with macular edema secondary to retinal vein occlusion (RVO). METHODS: Forty-four patients treated with intravitreal bevacizumab for unilateral macular edema due to RVO were retrospectively reviewed. Before injection, patients underwent best-corrected visual acuity (BCVA) assessment, dilated fundus examination, fluorescein angiography, and enhanced depth imaging optical coherence tomography. Changes in BCVA, SCT, and central macular thickness (CMT) of the RVO eyes were evaluated and compared with those of the normal contralateral eyes at baseline and at 1, 3, and 6 months after injection. RESULTS: The mean SCT in RVO eyes (265.41 ± 43.02 µm) was significantly thicker than that in the fellow eyes (244.77 ± 30.35 µm) at baseline (p < 0.001). The mean SCT was significantly reduced at 1, 3, and 6 months after intravitreal bevacizumab injection (all p < 0.001), and the change in SCT was significantly correlated with the change in CMT (r = 0.327, p = 0.030). While there was an improvement in BCVA together with a reduction in SCT (p < 0.001), no significant correlation was found (p = 0.126). CONCLUSIONS: Subfoveal choroidal thickness in RVO eyes with macular edema was greater than that in the normal fellow eyes, and decreased significantly after intravitreal bevacizumab injection. The SCT reduction was significantly correlated with CMT reduction.